analyzeportfolio
NYSE · Financials

Oscar Health, Inc. (OSCR)

As-reported financials and SEC filings for Oscar Health, Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Oscar Health, Inc.

Oscar Health, Inc. is a healthcare technology company that offers health insurance plans primarily through the Affordable Care Act marketplaces. It serves individuals, families, and employees by providing various metal-tier health plans and specialized products targeting conditions like diabetes and asthma. The company also operates a technology platform called +Oscar that supports providers and payors with engagement and analytics tools, and offers brokerage and enrollment services through acquired businesses.

Snapshot

Revenue
$11.70B
Revenue growth (YoY)
27.5%
Net income
$-443.2M
Diluted EPS
$-1.69
Gross margin
Operating margin
-3.4%
Net margin
-3.8%
FCF margin
9.0%
ROE
-45.2%
net income / fiscal-year-end equity
P/E
trailing when available, otherwise FY EPS
Market cap
$9.21B
Long-term debt / equity
0.44×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Oscar Health

  • Revenue grew 27.5% to $11.7B in FY2025, slower than the 56.5% the year before.
  • Operating margin is -3.4% in FY2025, +26.2 pp against -29.6% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $4.9B, up 70.4% from Q2 FY2025.
  • Free cash flow was $1.1B in FY2025, 9.0% of revenue.
  • Net income turned to a $443M loss in FY2025, from a $25M profit in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Oscar Health’s fundamentals sit among the 425 Financials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin-3.4%
26th percentile of 146
Net margin-3.8%
12th percentile of 377
FCF margin9.0%
31st percentile of 272
Revenue growth (YoY)+27.5%
76th percentile of 420
ROE-45.2%
9th percentile of 375
Long-term debt / equity0.44×
56th percentile of 194
Short interest2.34d
21st percentile of 420

Oscar Health’s return on equity of -45.2% ranks in the 9th percentile of the 375 Financials companies reporting it. Oscar Health’s net margin of -3.8% ranks in the 12th percentile of the 377 Financials companies reporting it.

No reported insider purchases (code P) in the last 90 days; 26 insider sales totaling $125.8M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 3 of the superinvestors we track (plus 7 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
3
+7 quant / multi-strat
Initiated / added
9
3 new, 6 added
Reduced / exited
1
1 trimmed, 0 exited
Combined position
$754.9M
reported long value
InvestorAs ofPosition valueSharesChange
D. E. ShawquantQ2 2026$360.6M12.6MAdded
Citadel AdvisorsquantQ2 2026$120.6M4.2MAdded
Two Sigma InvestmentsquantQ2 2026$115.1M4.0MAdded
Renaissance TechnologiesquantQ2 2026$93.7M3.3MNew
Point72 Asset ManagementquantQ2 2026$22.8M799.8KReduced
Millennium ManagementquantQ2 2026$18.3M641.4KAdded
AQR Capital ManagementquantQ2 2026$15.9M559.0KAdded
Bridgewater AssociatesQ2 2026$6.1M213.7KNew
Polen Capital ManagementQ2 2026$1.1M38.7KNew
Gotham Asset ManagementQ2 2026$708,63624.8KAdded

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
26
$125.8M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-28
filed 2026-08-31
Schlosser MarioDirectorSell150.0K$30.79$4.6M
2026-08-27
filed 2026-08-31
Schlosser MarioDirectorSell600.0K$30.34$18.2M
2026-08-18
filed 2026-08-20
Blackley Richard ScottChief Financial OfficerSell18.8K$31.74$595K
2026-07-01
filed 2026-07-06
Schlosser MarioDirectorSell30.2K$31.65$957K
2026-07-01
filed 2026-07-06
Schlosser MarioDirectorSell13.7K$30.80$421K
2026-07-01
filed 2026-07-06
Schlosser MarioDirectorSell3.6K$29.50$106K
2026-06-30
filed 2026-07-01
Bertolini Mark TChief Executive OfficerSell488.7K$28.35$13.9M
2026-06-30
filed 2026-07-01
Bertolini Mark TChief Executive OfficerSell135.6K$28.97$3.9M
2026-06-29
filed 2026-07-01
Bertolini Mark TChief Executive OfficerSell555.8K$29.17$16.2M
2026-06-29
filed 2026-07-01
Bertolini Mark TChief Executive OfficerSell58.9K$30.08$1.8M
2026-06-26
filed 2026-06-29
Bertolini Mark TChief Executive OfficerSell441.4K$29.11$12.8M
2026-06-26
filed 2026-06-29
Bertolini Mark TChief Executive OfficerSell149.8K$29.79$4.5M

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
16.4M
settled 2026-08-14
Change vs prior
-7.8%
vs previous settlement
Days to cover
2.34
at avg daily volume
Avg daily volume
7.0M
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-1416.4M-7.8%2.34
2026-07-3117.8M-8.9%4.08
2026-07-1519.6M+4.5%4.01
2026-06-3018.7M+7.3%2.74
2026-06-1517.5M-2.9%2.03
2026-05-2918.0M-2.1%2.57
2026-05-1518.4M-24.7%1.82
2026-04-3024.4M-6.7%4.46

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$11.70B$9.18B$5.86B$3.96B$1.84B
Gross profit
Operating income$-396.4M$57.3M$-235.6M$-589.9M$-544.5M
Net income$-443.2M$25.4M$-270.7M$-606.3M$-572.6M
Diluted EPS$-1.69$0.10$-1.22$-2.85$-3.20

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$1.09B$978.2M$-272.2M$380.3M$-181.7M
Capital expenditure$36.4M$27.9M$25.6M$29.0M$25.9M
Free cash flow$1.06B$950.3M$-297.7M$351.3M$-207.6M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$4.88B70.4%$361.8M$1.10
Q1 FY2026$4.65B52.6%$679.0M$2.07
Q4 FY2025$2.81B17.3%$-352.6M$-1.25
Q3 FY2025$2.99B23.2%$-137.4M$-0.53
Q2 FY2025$2.86B29.0%$-228.4M$-0.89
Q1 FY2025$3.05B42.2%$275.3M$0.92
Q4 FY2024$2.39B67.1%$-153.5M
Q3 FY2024$2.42B68.3%$-54.6M$-0.22

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNYSE
SectorFinancials
SIC industryHospital & Medical Service Plans
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2013
SEC CIK1568651

Selected SEC filings

10-Q2026-08-07
View on EDGAR →
10-Q2026-05-07
View on EDGAR →
8-K2026-08-06
View on EDGAR →
8-K2026-06-09
View on EDGAR →
8-K2026-06-08
View on EDGAR →
8-K2026-06-02
View on EDGAR →

Largest Financials peers

All Financials companies →

Monitor OSCR

Get an alert when Oscar Health files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor OSCR free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.